The results indicate that the patients receiving lymphadenectomy followed by anti-CTLA4 therapy have a significantly reduced risk of developing lymphedema compared to untreated patients or patients receiving a different immune checkpoint inhibitor scheme. This evidence concerns the gene CTLA4 and lymphedema.